HLB Therapeutics (115450) Fundamentals 2026 — Revenue Analysis | SniperIQ
HLB Therapeutics (115450) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩147.5B, trading at ₩1673.00 on the KOE. This SniperIQ fundamentals page covers HLB Therapeutics's valuation, profitability (net margin -10.8%), revenue (₩69.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is HLB Therapeutics's market cap?
HLB Therapeutics (115450) has a market capitalization of approximately ₩147.5B, trading at ₩1673.00 on the KOE. Market cap moves with the live share price.
What is HLB Therapeutics's P/E ratio?
HLB Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is HLB Therapeutics?
HLB Therapeutics runs a net profit margin of -10.8%, a gross margin of 11.2%, and an operating margin of -7.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does HLB Therapeutics generate?
HLB Therapeutics reported revenue of ₩69.7B for fiscal year 2025, with net income of -₩9.2B and earnings per share (EPS) of -100. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does HLB Therapeutics pay a dividend?
HLB Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is HLB Therapeutics financially healthy?
HLB Therapeutics carries a debt-to-equity ratio of 0.27x and a current ratio of 1.34x, with a market beta of -0.70. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is HLB Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For HLB Therapeutics (115450) the key facts are: market cap ₩147.5B, revenue ₩69.7B, 52-week range 1342-4160. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track HLB Therapeutics's full fundamentals live
Get HLB Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.